PharmaVoice

Stay informed with the latest pharma industry news and insights by signing up for PharmaVoice. Explore all our free newsletter options here: https://lnkd.in/gP2m_c7J

Working in the rare disease space often means blazing a new trail — whether it’s in drug development for an illness with no approved medications or building bridges to help patients cross the access divide. Check out this year’s slate of Rare Disease Warriors in the 2024 PharmaVoice 100 class who are currently dedicating their careers to these lofty pursuits. Dr. Soraya Bekkali, MD, Alexion Pharmaceuticals, Inc. Dr. Heather Lau MD MS, Ultragenyx Carlos Martin, Rocket Pharmaceuticals Bill Rote, Travere Therapeutics Cheryl Schwartz, Takeda #rarediseases #genetherapy #oncology #kidneydisease #leadership #biotech https://lnkd.in/e7X_GQKB

As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in #COPD. "We’ve come a long way in advancing the science and following it to make a difference," says Dr. Donna Carstens MD, senior medical director for the biologic respiratory drug Fasenra at AstraZeneca. https://lnkd.in/e28iWme2

As biologics come to the fore against #COPD, AstraZeneca seeks to overcome its past trial stumbles with Fasenra to join the fray. A deeper focus on the patients who will respond best could be the key, says Donna Carstens MD. Read more at PharmaVoice.

As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough. Erin Duffy, CARB-X Seres Therapeutics #superbug #pharma https://lnkd.in/eneH9abc

After a slow start, the novel esketamine nasal spray Spravato for depression is now Johnson & Johnson’s fastest-growing medication. “We always knew it would take time to see significant uptake — new models of care always do — but the overwhelming patient need continues to drive treatment center expansion,” says Bill Martin, PhD, global neuroscience therapeutic area head at Johnson & Johnson Innovative Medicine. #depression #spravato #neuroscience #pharma https://lnkd.in/eyFigMMV

Biotech is where ideas in the life sciences gain traction to become the medicines of tomorrow. And while these ideas hold great potential, biotech leaders often need to chart a difficult course to bring them to fruition. Here are this year’s PharmaVoice 100 Biotech Pathfinders. Shelley Force Aldred, Rondo Therapeutics Lyn Baranowski, Avalyn Pharma Jared Bearss, Halia Therapeutics, Inc. Howard Berman, PhD, Coya Therapeutics, Inc. Sarah Boyce, Avidity Biosciences, Inc. Dr. Michael Ehlers, Ascidian Therapeutics, ATP (Apple Tree Partners) Julie Gilmore, Eli Lilly and Company, Lilly Gateway Labs Jennifer Good, Trevi Therapeutics, Inc. Avak Kahvejian, Flagship Pioneering Dr. Andy Scharenberg, Umoja Biopharma Mari Anne Snow, Eascra Biotech Ryan Spencer, Dynavax Technologies Brian Taylor, SmartLabs #biotechnology #leadership #immunology #oncology #biotechVC #obesity #PV100 #PharmaVoice https://lnkd.in/esw_hy-E

As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm. “Dengue is moving, and we are starting to get a ton of locally acquired dengue fever cases in the U.S., specifically in Puerto Rico, Virgin Islands and Florida,” says Katelyn Jetelina, an epidemiologist and data scientist. #Dengvaxia Takeda #Qdenga Derek Wallace Andre Siqueira, Drugs for Neglected Diseases initiative - DNDi World Health Organization https://lnkd.in/gfuF9eVU

Activist investing is on the rise. With Starboard leveraging its position in Pfizer to address the post-pandemic slump, we're exploring what motivates shareholders to take an activist role in #pharma and other sectors with commentary from Buchalter's Steve Segal. Read more at PharmaVoice.

It’s not every day in pharma that a new class of drugs enters the pantheon of the best-selling medications of all time. But the emergence of Eli Lilly and Company’s #Zepbound and #Mounjaro and Novo Nordisk’s #Ozempic and #Wegovy took the #pharma world by storm. In keeping with the times, the PharmaVoice 100 introduced a new category this year to recognize the significant impact of this market. These leaders include Big Pharma players making an impact by turning GLP-1s into household names, and those pushing the boundaries with novel approvals. Meet the Cardiometabolic All-Stars! Robert Blum, Cytokinetics Kristen Fortney, BioAge Labs Dr. Vipin Garg, Altimmune, Inc. Negelle Morris, Novo Nordisk Rohan Palekar, 89bio Dr. Rebecca Taub, Madrigal Pharmaceuticals https://lnkd.in/e9uYrwBj